Skip to main content
. Author manuscript; available in PMC: 2014 Nov 27.
Published in final edited form as: Cancer Gene Ther. 2014 Oct 17;21(11):472–482. doi: 10.1038/cgt.2014.53

Figure 2.

Figure 2

Bortezomib enhances CID-induced apoptosis of iC9-transduced cells. (a) Non transduced and iC9-transduced NSCLC cell lines were left untreated or treated with bortezomib (80 nM) in the presence or absence of CID (80 nM) as indicated. Apoptosis was assessed by flow cytometry for Annexin V binding and 7-AAD staining 24 hours after treatment. Error bars represent standard deviation. (b) iC9-transduced A549 and H1299 cells were treated with the indicated amounts of CID, bortezomib or a combination of both. Apoptosis was assessed by flow cytometry for Annexin V binding and 7-AAD staining 24 hours after treatment (see Figure S2). Dose-effect curves were plotted using CalcuSyn™ software. (c) Combination indices were calculated from the data in (b) and plotted using CalcuSyn™ software. CI value less than 1.0 is considered synergistic.